Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Driven by innovation and ESG practices, Health and Genesis' global competitiveness continues to rise.

Time Posted:2024-07-29 14:35

Recently, Joincare Pharmaceutical Group Industry Co., Ltd. stood out from over 1700 Chinese companies across 60 industries, based on its outstanding performance in Environmental, Social, and Governance (ESG) criteria. It was successfully included in S&P Global's Sustainability Yearbook (China Edition) 2024 for the first time, becoming one of the five pharmaceutical companies selected. This highlights the company's achievements and influence in the field of sustainable development.

Health Yuan: Grasping the main line of innovative development and forming a diversified product matrix

Time Posted:2024-07-27 16:00

HealthGen, a veteran biopharmaceutical company with over 20 years of market experience, has accelerated its expansion from health products to pharmaceuticals, establishing multiple R&D platforms for innovative drugs and high-barrier complex formulations.

Deep into the Qiangtang hinterland: Healthy Yuan & Lizhu Group's chronic disease public welfare supports the red Gaize

Time Posted:2024-07-23 10:45

Guided by the national "Healthy China 2030" strategy, Health Yuan Group actively responded to the national call and is committed to improving the level of primary medical services. Recently, a donation ceremony for chronic disease prevention and public welfare to support rural revitalization, jointly organized by Health Yuan & Lizhu Pharmaceutical Group, was held in the Gaize County Government Square. Zhang Chengwei, Deputy County Head; Cidan Wangjiu, Director of the County Health and Health Commission; Han Fengyuan, Organization Department of Bomê County Committee (Ali Regional Committee Organization Department In-service Training); relevant leaders from the County Health and Health Commission, People's Hospital, and Red Cross Society; presidents of health centers in various townships; and volunteers from Health Yuan and Lizhu Group attended the event.

Lizhu Pharmaceutical and NeuroSense Therapeutics have reached an exclusive license agreement for Greater China for NS-041, a highly selective KCNQ2/3 activator.

Time Posted:2024-07-18 16:35

Recently, Lizhu Pharmaceutical Factory of Lizhu Group Co., Ltd. (hereinafter referred to as "Lizhu Pharmaceutical"), a wholly-owned subsidiary of Lizhu Pharmaceutical Group Co., Ltd., and Neurosyn Pharma (Shanghai) Co., Ltd. (hereinafter referred to as "Neurosyn Pharma"), an international biotechnology company focusing on the development of innovative therapies for neurological and psychiatric diseases, reached an exclusive license agreement for Greater China for NS-041, a small molecule drug candidate owned by Neurosyn Pharma globally. Both parties will closely cooperate on the basis of this agreement to accelerate the listing process of NS-041.

Sustainability Leadership | Healthy Yuan Included in S&P Global's Sustainability Yearbook (China) 2024 for the First Time

Time Posted:2024-07-17 16:00

On July 16, S&P Global released the "2024 Sustainability Yearbook (China Edition)", featuring 129 leading industry companies. Joincare Pharmaceutical Group Industry Co., Ltd. stood out from over 1700 assessed Chinese companies across 60 industries due to its outstanding performance in Environmental, Social, and Governance (ESG) criteria. It was successfully included in the "2024 Sustainability Yearbook (China Edition)" for the first time, becoming one of the five pharmaceutical companies selected, demonstrating the company's achievements and influence in sustainable development.

Innovation and Quality Improvement: Healthy Element Focuses on Innovative Drugs and High-Barrier Complex Formulations R&D to Achieve High-Quality Development

Time Posted:2024-07-12 10:00

The innovative drug industry is receiving another policy boost. On July 5, the State Council executive meeting reviewed and approved the "Implementation Plan for Supporting the Development of Innovative Drugs Across the Entire Chain", marking a transition for China's domestic innovative drug industry from the research and development investment stage to the value realization stage.

Moment of Glory! The 2023 Top 100 Chinese Pharmaceutical Industry Rankings Released

Time Posted:2024-06-25 20:50

Recently, the adjustment of the 2024 National Medical Insurance Catalog was officially launched. Before this, the key tasks for the 2024 deepening of medical and health system reform were released. In addition to the first official announcement of full-chain support for innovative drugs, adjustments to the essential drug list and the expansion of high-quality volume-based procurement are imminent...

Hundreds of millions of imitations! Jiankangyuan's "Asthma Inhalation Powder" approved for market

Time Posted:2024-06-14 11:37

During the week of June 3rd to 9th, a total of 87 varieties passed/were deemed to have passed the consistency evaluation. Among them, Health Yuan's salmeterol/fluticasone propionate powder inhaler is a first-to-market drug. During the same period, 81 varieties applied for consistency evaluation.

< 1...8910...55 >